CNBC 快讯 5月13日 15:30 靶向衰老领域的制药标的年内已大涨，BTIG认为仍有翻倍空间 This pharma name targeting aging has soared this year. BTIG thinks it can double from here The investment firm initiated coverage of the biopharmaceutical name with a buy rating. FG 100 读报告 →